Insights

  • Home
  • Insights
  • PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent, PTAB Litigation Blog

Share

PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent, <i>PTAB Litigation Blog</i>

PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent, PTAB Litigation Blog

February 2017 Blog

Visit the Jones Day PTAB Litigation Blog.

On February 3, 2017, the PTAB denied a petition by Amneal Pharmaceuticals LLC ("Amneal") to institute an inter partes review of Hospira Inc.’s patent directed to pharmaceutical compositions of the sedative dexmedetomidine.

Read the full article at ptablitigationblog.com.

You May Also Be Interested In

April 2024 Blog

Common Ownership Exception Leads to Petition Denial, PTAB Litigation Blog

April 2024 Blog

“Known” Claim Elements Alone Insufficient for Motivation to Combine, PTAB Litigation Blog

April 2024 Alert

USPTO Issues New Guidance on Practitioners' Use of AI

April 2024 White Paper

Fifteenth Anniversary Update: Annotated Local Patent Rules for the Northern District of Illinois

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.